Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Budman33 I don't think anyone knows at this point
All that is known is whatever the price closes at Thursday will be the price until Monday ☺
Do we close higher today and what's the guesstimate fo Friday
And you believe the Grifter 😂
It has been more than $ 68 in the past, so what does that mean then in your opinion?
I never said it was guaranteed but everyone knows it is foolish not to check the history in order to be more centered when picking up a stock. Economic 101. History is a great factor for a real investor to use. Period
Things in the past are no guarantee for the future!
Good follow through and we trade at .02+
That is a great gamble on a double down.
No, you are the one who knows it all
That’s your problem, you never stop for a second to check on history!!!
Or full one coin and buy 4-5 M
I may sell my 1/2 bitcoin and use that money to buy Vdrm.at11AM
Fdc4 U know nothing more than anyone else
A few times $$ 😀 hopefully couple more
Bought back 2 mill @ .01 So little do U know
Fdc4 I have already made a nice profit here & U ?
Fdc4 That's your problem always looking backwards
That mentality is what got you stuck in here for years in first place. Be realistic, think small and aim big. One day at a time, Otiko hasn’t revealed the goodies yet. Not goodies, this could reach up to $0.10 cents but that’s about it mate. History speaks for itself
Beninvest if it keeps running post a pic.
Fdc4 I'm not here for .07 that's chump change
Case of beer and some ammo!!
Let’s go VDRM!
She buying you new nuts ?
This keeps running my wife gets new tits!!!
What I am certain is that the PPS will fly over $0.07 cents for sure
Yes it’s been a long time but sold some at times for a nice profit hopefully he comes through again, I think he will but will definitely sell enough for a profit and ride free plus have 1 mil locked in at the lottery price $1.00 $$$$$
Sub penny will be history for ever after filings.
And Beyond!!!!
And Beyond!!!!
MLK Alias Born 04/08/2022
Search Member Posts
2023
About
Latest Posts
Boards Posted On
Boards Moderated
My Stocks
FInal pump...he'll be out Monday....on to the next Grift...
I believe he will deliver. Been a slow multi year start
I don’t think that’s the way it works. The fillings does not have to do nothing with the states contracts. The fillings are just documents showing what the company has been doing, nothing else: Transparency to the people… The contracts could be already done without him filling in. Do you get the logic. Relax, the Doc seems to have made the few first steps forward to the right direction. There’s not reason for failure from this point. He will deliver
I got you $weet$$$
Risk equals rewards my brothers, that’s how it works
Great run on Friday, more to come soon!
You can pump all you want but no one running out to buy shares based on your reco
I'm sure ORCA will thank you and go easy
Go easy and watch strong opening at premarket , can not trade premarket but 9:30AM bid and ask will be nasty upside move.They may 🛑 stop or halt for trading if huge buy orders come in.
Do whatever you want I am looking big jackpot on this stock
Go easy and watch strong opening at premarket , can not trade premarket but 9:30AM bid and ask will be nasty upside move.They may 🛑 stop or halt for trading if huge buy orders come in.
Do whatever you want I am looking big jackpot on this stock
Go easy and watch strong opening at premarket , can not trade premarket but 9:30AM bid and ask will be nasty upside move.They may 🛑 stop or halt for trading if huge buy orders come in.
Trust but verify is always necessary, especially with this company. However, they did make the below X post on February 1st. Thus, it will, as a minimum, have to be in the 1Q24 Financial Report issued around May 15, 2024 (hopefully). Admittedly I do not know the applicable rules, but it could possibly be added as supplementary information in 2023 Annual Report, expected on or before March 30, 2024. By the way, $1.2M is all but about $0.2M of the projected Accounts Receivable balance through Jan 2024, which would be significant step in right direction. However, trust but verify still applies and is necessary.
Cannot receive if not due, hmmm.
Followers
|
619
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
74600
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |